Chotalin

Chlortalidone

Adjunctive therapy in edema associated w/ CHF, hepatic failure & cirrhosis, & corticosteroid & estrogen therapy. Monotherapy or in combination w/ other classes of antihypertensive agents for all stages of HTN. Neurohypophyseal & nephrogenic diabetes insipidus.

Individualized dose. Edema Initial: 50-100 mg daily in a single dose. Alternatively, initiate 100 mg every other day or 3 times a wk. HTN Adult Initial: 12.5 mg once daily. Target dose: 12.5-25 mg once daily. Max: 25 mg once daily. Elderly Initial: 12.5-25 mg once daily or every other day. Diabetes insipidus Initial: 100 mg bid. Maintenance dose: 50 mg daily.

Should be taken with food: Take w/ breakfast.

Hypersensitivity to chlorthalidone, other sulfonamide-derivative drugs, or any component of the formulation, renal decompensation, hepatic coma or precoma, anuria. History of gout or elevated uric acid conc. Pregnancy (w/ mild edema).

Severe renal disease, impaired hepatic function, or progressive renal or liver disease. Discontinue if signs of impending hepatic coma occur. History of allergy or bronchial asthma. Possible exacerbation or activation of systemic lupus erythematosus. Observe for signs of electrolyte imbalance. Perform periodic determination of serum electrolyte conc eg, K, Na, chloride & bicarbonate wkly or frequently early in the course of treatment. Hypokalemia, hypochloremia, hyponatremia, hyperuricemia, hypomagnesemia, hypercalcemia, hyperglycemia, & glycosuria. Avoid use of K-sparing diuretics, K supplements or food w/ high K content to treat hypokalemia. Geriatric patients especially females who are underwt, poor oral intake of fluid & electrolytes, &/or excessive intake of low Na nutritional supplements. Patients receiving vit D or having mild hyperparathyroidism. Post-sympathectomy patients. Moderate or high cholesterol conc & in patients w/ elevated triglyceride levels. Lactation. Childn. Elderly.

Hypokalemia, hyperuricemia, blood lipid rise, hyponatremia, hypomagnesemia, hyperglycemia, gout, hypercalcemia, glycosuria, worsening of diabetic metabolic state, hypochloremic alkalosis; orthostatic hypotension, cardiac arrhythmias; anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis; dizziness, vertigo, paresthesias, headache, xanthopsia; leukopenia, hemolytic anemia, agranulocytosis, thrombocytopenia, aplastic anemia, eosinophilia; purpura, photosensitivity dermatitis, rash, urticaria, necrotizing angiitis (vasculitis, cutaneous vasculitis), exfoliative dermatitis/TEN; reduced libido/impotence; muscle cramp/spasm, allergic interstitial nephritis, weakness, restlessness, idiosyncratic pulmonary oedema (resp disorder).

May potentiate action of other antihypertensive drugs. Potentiated hypokalemic effects by corticosteroids, corticotropin, amphotericin B. May precipitate digitalis-induced cardiac toxicity w/ thiazide-induced electrolyte disturbances. Increase responsiveness of tubocurarine. Decrease arterial responsiveness of vasopressors (eg, norepinephrine). Increase toxicity of lithium. Enhanced biological effects of vit D. Hypercalcemia may occur w/ Ca salts. Reduced diuretic, natriuretic, & antihypertensive effects w/ NSAIDs (eg, indomethacin). Allopurinol. Enhance hyperglycemic effect of diazoxide. Reduce anticoagulant effect of anticoagulants. Reduced GI absorption w/ cholestyramine or colestipol resin. Increased absorption w/ anticholinergics.

Diuretics

C03BA04 - chlortalidone ; Belongs to the class of low-ceiling sulfonamide diuretics.

D